FKBPL-based therapeutic peptide mimetic, AD-01 (preclinical peptide candidate), has showed a potent anti-angiogenic and anti-cancer stem cell effects in cancer via CD44 and DLL4 (Yakkundi et al., 2013; McClements et al., 2013; Annett et al., 2020). This evidence concerns the gene CD44 and cancer.